Miakaltsik - instruction , application reviews

Miacalcic is a medicament that affects the phosphorus-calcium metabolism used to treat osteoporosis.

Active ingredient

Calcitonin( Calcitonin)


Produced in the form of a clear, colorless solution for injection and a clear nasal spray. Solution for injections is realized in ampoules of 1 ml, in cardboard packs( 5 ampoules each), and nasal spray - in bottles with a nebulizer in cardboard packs( 1 or 2 bottles each).


Solution for injection

1 ml

synthetic salmon calcitonin( 1 IU - 0.2 μg synthetic salmon calcitonin)

100 IU

Excipients: sodium acetate trihydrate, acetic acid, water for injection, sodium chloride.

nasal spray 1 ml

synthetic salmon calcitonin

200 IU

Excipients: hydrochloric acid, sodium chloride, benzalkonium chloride, purified water.


General indications for both forms of Mycatzik are:

  • Deforming osteitis( Paget's disease).
  • Bone pain( ossalgia) associated with osteopenia or osteolysis.
  • Postmenopausal osteoporosis.
  • Neurodystrophic diseases due to such predisposing and etiological factors as: reflex degeneration, posttraumatic painful osteoporosis, medicinal neurotrophic disorders, causalgia, humerus syndrome.

In the form of a solution for injections appointed at the following pathological conditions:

  • Primary osteoporosis.
  • Secondary osteoporosis.
  • Osteolysis caused by a malignant tumor.
  • Intoxication with vitamin D.
  • Hypercalcemic crisis.
  • Chronic hypercalcemia.
  • Hyperparathyroidism.
  • Acute pancreatitis( as part of complex therapy).


The only contraindication to use is the individual intolerance of the active ingredient or one of the excipients.

Method of application

Miacalcic in the form of a solution for injection is administered subcutaneously, intramuscularly and intravenously.

In osteoporosis, the drug is administered intramuscularly or subcutaneously at a daily dose of 50-100 IU every day or every other day.

With Paget's disease, Mikaltsik is administered intramuscularly or subcutaneously. The daily dose of the drug is 100 IU.Injections are done daily or every other day. The duration of therapy is at least 3 months.

For bone pain associated with osteopenia or osteolysis, the daily dose of the drug varies from 100 to 200 IU.With osalgia injected intramuscularly, subcutaneously or intravenously drip. Injections for pain in the bones are done daily.

With hypercalcemic crisis, the drug, diluted in 500 ml of physiological solution, is administered intravenously drip for 6 hours. The daily dose is 5-10 IU / kg. Also, intravenous jet flow is slow. In this case, the daily dose is divided into 2-4 injections.

For chronic hypercalcemia, the drug is administered intramuscularly or subcutaneously. The daily dose is 5-10 IU / kg.

In case of neurodegenerative diseases, Mikaltsik is administered intramuscularly or subcutaneously. The daily dose is 100 IU.The duration of therapy varies from 2 to 4 weeks.

In acute pancreatitis, Miakaltsik, diluted in physiological saline, is administered intravenously drip. The daily dose is 300 IU.The drug is administered for 24 hours. Duration of treatment - 6 days.

Intranasal administration to the nasal passages should be performed alternately.

In osteoporosis, the recommended daily dose is 200 IU.

With osalgia, the daily dose of nasal spray varies from 200 to 400 IU.The drug is applied daily.200 IU can be entered for 1 time. A dose exceeding 200 IU should be divided into several injections.

With Paget's disease, the daily dose of Miakaltsik is 200 IU.Sometimes at the beginning of therapy, the daily dose of nasal spray is 400 IU.Duration of treatment - from 3 months to several years.

In case of neurodystrophic diseases, the daily dose of the drug is 200 IU.Miakaltsik used daily for 2-4 weeks.

Side effects of

The use of Miacalcic can cause the following side effects:

  • Immune system: rarely - hypersensitivity;very rarely - anaphylactoid or anaphylactic reactions, anaphylactic shock.
  • Gastrointestinal tract: often - abdominal pain, diarrhea, nausea;sometimes - vomiting.
  • Cardiovascular system: often - hot flashes;sometimes - increased blood pressure.
  • Urinary system: rarely - polyuria.
  • Nervous system: often - dizziness, headache.
  • Musculoskeletal system and connective tissue: often - arthralgia;sometimes - myalgia and ossalgia.
  • Respiratory system( with nasal spray): very often - rhinitis, sneezing, congestion, soreness of the nasal cavity, allergic rhinitis, nasal congestion, dryness in the nasal cavity, erythema of the nasal mucosa, unpleasant odor, irritation, formation of excoriations innose;often - sinusitis, pharyngitis, nosebleeds, ulcer rhinitis;sometimes - a cough.
  • Sensory organs: often - flavors;sometimes - visual disturbances.
  • Skin and subcutaneous tissue: rarely - generalized rash.
  • Other: often - increased fatigue;sometimes - edema of the face, generalized and peripheral edema, influenza-like syndrome;rarely - chills, itching and reactions at the injection site.

The use of Mikaltsik in high doses can lead to symptoms such as: dizziness, hot flashes, nausea and vomiting. Also, with an overdose, hypocalcemia may occur.

Overdose treatment is symptomatic. With hypocalcemia, calcium gluconate is prescribed.

Special instructions

Before intramuscular and subcutaneous injection, the solution must be heated to room temperature.

Do not shake the bottle before using Miacalcic in the form of a nasal spray, as this may cause the formation of air bubbles in the vial, which will lead to an incorrect dosage of the drug.

Some side effects of the drug( visual disturbances, dizziness) can adversely affect the ability to drive and perform potentially dangerous jobs requiring rapidity of psychomotor reactions and increased concentration.

With Paget's disease, the duration of therapy with Mycalficom should be between 3 months and several years. Prolonged use of the drug may trigger the formation of antibodies to calcitonin, but this does not affect clinical effectiveness.

To avoid the development of an allergic reaction, skin tests should be performed before the start of treatment. To do this, use diluted sterile solution Miakaltsik.

Drug Interaction

Combination of Mycatalc with lithium preparations can lead to a decrease in plasma lithium concentration.

Storage conditions and storage conditions

Store in a place protected from direct sunlight and out of reach of children, at a temperature of 2 to 8 ° C.

Shelf life of the nasal spray is 3 years, injection solution is 5 years.

After the expiry date, the drug is strictly prohibited.


1. Active substance

2. Form

3. Composition

4. Indications

5. Contraindications

6. How to use

7. Side effects of

8. Special instructions

9. Drug Interaction

10. Terms and Conditions of Storage


Description of the drug, placed on this page, is a supplemented and simplified version of the official version of the annotation to the drug. The information is provided for informational purposes only and is not a guide for self-treatment. Before using the drug, you should consult a specialist and read the instructions approved by the manufacturer.

Latest Blog Post

Rabies vaccine - instruction , application reviews
August 12, 2017

Contents: 1. Product form inactivated rabies vaccine 2. Pharmacological action 3. Indications for use of rabies vaccine 4. Co...

Antipsoriaz - instruction , application reviews
August 12, 2017

Contents: 1. release form and composition Antipsoriaza 2. Pharmacological action 3. Indications ointment Antipsoriaz 4. Dosag...

Antipolitsay - action guide , application reviews
August 12, 2017

Contents: 1. Pharmacological action 2. Structure and Composition 3. Instruction Antipolitsayu 4. Contraindications and side e...